Spots Global Cancer Trial Database for drug resistance
Every month we try and update this database with for drug resistance cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma | NCT00054665 | B-Cell Lymphoma | PS-341 Etoposide Doxorubicin Vincristine Cyclophosphamid... Prednisone Filgrastim | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas | NCT00001430 | Hodgkin's Disea... Non Hodgkin's L... | PBSC IL-2 EPOCH II | - | National Institutes of Health Clinical Center (CC) | |
| Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity | NCT02183883 | Non-small Cell ... | Afatinib | 18 Years - | University College, London | |
| The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | NCT06117644 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Furmonertinib | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| Collection of Blood, Bone Marrow, Tumor or Tissue Samples | NCT00043615 | Neoplasms Precancerous Co... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors | NCT06403436 | Advanced Solid ... Adult Solid Tum... Adult Disease Cancer | TT125-802 | 18 Years - | TOLREMO therapeutics AG | |
| The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | NCT06117644 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Furmonertinib | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | |
| The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | NCT01968928 | Bladder Urothel... | 20 Years - 80 Years | National Taiwan University Hospital | ||
| HRD and Resistance to PAPPi in EOC Patients | NCT05310370 | Epithelial Ovar... Homologous Reco... Homologous Reco... Poly(ADP-ribose... Drug Resistance Progression-fre... Overall Surviva... | Testing of homo... | 18 Years - | Peking Union Medical College Hospital | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors | NCT06403436 | Advanced Solid ... Adult Solid Tum... Adult Disease Cancer | TT125-802 | 18 Years - | TOLREMO therapeutics AG | |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | NCT00972205 | Cervical Ovarian Lung Breast Renal | paclitaxel CBT-1(Registere... Tc 99m sestamib... | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| HRD and Resistance to PAPPi in EOC Patients | NCT05310370 | Epithelial Ovar... Homologous Reco... Homologous Reco... Poly(ADP-ribose... Drug Resistance Progression-fre... Overall Surviva... | Testing of homo... | 18 Years - | Peking Union Medical College Hospital | |
| Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer | NCT00738777 | Breast Cancer | Anastrozole Anastrozole+Ful... Tamoxifen Tamoxifen | - | The Netherlands Cancer Institute | |
| Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia | NCT01437202 | Leukemia, Myelo... | 18 Years - | Asan Medical Center | ||
| Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab | NCT03919539 | Drug Resistance... Biomarkers for ... | 5hmc testing | 12 Years - | Peking University People's Hospital | |
| Vinorelbine and XR9576 to Treat Cancer | NCT00001944 | Breast Cancer Cancer Lung Cancer Ovarian Cancer | Vinorelbine XR9576 | - | National Institutes of Health Clinical Center (CC) | |
| The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma | NCT01968928 | Bladder Urothel... | 20 Years - 80 Years | National Taiwan University Hospital | ||
| The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment | NCT03401957 | Colorectal Canc... Drug Resistance Mass Spectromet... RAS-RAF Pathway... | Cetuximab liquid biopsy | 20 Years - 90 Years | National Health Research Institutes, Taiwan | |
| MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma | NCT01415765 | Lymphoma, Diffu... Diffuse, Large ... Lymphoma, Diffu... Large-Cell Lymp... | MLN4924 Etoposide Prednisone Vincristine Cyclophosphamid... Doxorubicin Rituximab Filgrastim | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Vinorelbine and XR9576 to Treat Cancer | NCT00001944 | Breast Cancer Cancer Lung Cancer Ovarian Cancer | Vinorelbine XR9576 | - | National Institutes of Health Clinical Center (CC) | |
| The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC | NCT06117644 | Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ... | Furmonertinib | 18 Years - | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
